New insider activity at Guardant Health ( (GH) ) has taken place on December 18, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Director Tariq Musa has recently sold 116 shares of Guardant Health stock in a transaction valued at $11,769, reflecting a modest insider sale at the company.
Recent Updates on GH stock
Over the last day, Guardant Health has seen a flurry of upward price target revisions driven more by improving fundamentals and sector outlook than by any single new announcement. Mizuho’s increase is tied to its 2026 outlook for medical devices and diagnostics, arguing that even after post‑Q3 gains there is room for further multiple expansion if AI and cryptocurrency trades keep risk capital elsewhere and healthcare remains the preferred defensive sector. BofA’s revision reflects a broader reset of Life Sciences & Diagnostic Tools coverage, with expectations that current headwinds will fade and markets normalize by 2026, and with particular emphasis on a rebound in biopharma R&D spending benefiting companies like Guardant that are more exposed to that budget. Leerink’s higher target stems directly from Guardant’s very strong Q3 performance and the firm’s view that momentum across its product portfolio is strengthening, leading it to model materially higher 2026 revenues and greater upside potential. JPMorgan’s change comes from updated models across the life science tools and diagnostics group, incorporating Guardant’s improved growth trajectory, while Wells Fargo’s increase is supported by easing U.S. policy uncertainty around pharma and a more favorable setup for tools names, with growth expectations seen as achievable and with room for positive surprises. These upgrades collectively underscore growing confidence in Guardant’s long‑term growth profile and in a more supportive macro backdrop for diagnostics and life science tools, which has underpinned recent strength in the stock following its Q3 results.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
Guardant Health’s strong technical momentum and positive earnings call insights are offset by financial instability and valuation concerns. Strategic partnerships and recent corporate events provide a supportive backdrop for future growth, but profitability and financial health remain critical areas for improvement.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
YTD Price Performance: 206.80%
Average Trading Volume: 2,637,756
Technical Sentiment Signal: Buy
Current Market Cap: $12.94B